Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S. (Reuters) - Pfizer Inc said on Friday ...

The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. That’s despite Ibrance’s ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...

Those were the findings of the phase 3 PALOMA-3 trial, presented May 30 during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology ...

Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because new rivals are stealing its share. The fast-growing blockbuster still boasts a 91% share of the CDK 4/6 ...